2026 Update: Hims' GLP-1 Medication Lineup Changed Significantly
In February 2026, Hims launched a compounded oral semaglutide pill, which it suspended shortly after following a legal dispute with Novo Nordisk (the patent holder for Wegovy and Ozempic). The companies settled in March 2026, and Hims signed a direct supply agreement to offer Novo Nordisk's FDA-approved Wegovy and Ozempic on its platform, alongside Eli Lilly's Zepbound. Hims has stated it is winding down its compounded semaglutide offering in favor of this broader branded lineup, with the transition targeted for completion by mid-2026. This review reflects the current, transitioning state of Hims' program — verify directly at hims.com what medication options are currently available, as this has changed multiple times in 2026.
Quick Snapshot: Three Platforms, Three Different Strengths
Hims Weight Loss: Deep Dive
Hims (Hims & Hers Health) — Transitioning to a Branded Model
Hims launched in 2017 as a men's health telehealth platform and grew into one of the largest direct-to-consumer health companies in the US (NYSE: HIMS). Its weight loss program historically centered on compounded semaglutide at low entry prices, but 2026 brought a significant strategic shift: following the Novo Nordisk legal dispute and subsequent settlement, Hims signed a direct supply agreement to offer FDA-approved Wegovy and Ozempic (and Eli Lilly's Zepbound), and has stated it is winding down compounded semaglutide in favor of this branded lineup.
Under the Novo Nordisk supply agreement, Hims has offered injectable Wegovy (across dose tiers) at approximately $299/month self-pay — competitive with other major telehealth platforms' brand-name pricing, though notably higher than compounded alternatives. Whether compounded semaglutide remains available on Hims' platform at all, and in what form, should be verified directly, as the transition has been described as ongoing through mid-2026.
Hims covers dozens of health categories beyond weight loss, meaning its providers are generalists rather than weight management specialists. For patients who specifically want the FDA-approved brand product and are comfortable with the current self-pay pricing, Hims' Novo Nordisk partnership is a legitimate option. For patients seeking the lowest-cost compounded pathway, the comparison has changed substantially from Hims' earlier positioning.
✓ Hims Strengths
- Direct Novo Nordisk supply agreement for authentic Wegovy/Ozempic
- Large publicly traded company — platform stability
- Polished app experience
- Multi-condition platform convenience
✗ Hims Limitations
- Compounded semaglutide availability uncertain — verify directly
- Branded Wegovy at ~$299/mo is higher than compounded alternatives
- Generalist model — not GLP-1 specialist
- Medication lineup has changed multiple times in 2026
Ro Body: Deep Dive
Ro Body — Clinical Depth + Integrated Pharmacy Model
Ro (formerly Roman) launched in 2017 with a men's health focus and developed its dedicated weight management division, Ro Body, as GLP-1 medications became mainstream. Ro's differentiator compared to Hims is clinical depth: Ro emphasizes video consultations with providers rather than purely asynchronous questionnaire review, optional metabolic lab work to inform treatment decisions, structured check-ins, and a more engaged clinical relationship throughout the treatment course.
Ro also operates its own integrated pharmacy facilities — a meaningful structural distinction from platforms that outsource to third-party compounders. This integrated pharmacy model provides Ro with more direct quality control over medication preparation and a stronger pathway for insurance coordination for brand-name Wegovy or Zepbound. Ro has been operating for 8+ years with substantial institutional backing, providing platform longevity that newer compounded GLP-1 providers cannot match.
Ro's limitations are primarily cost-related: Ro's actual billing separates a ~$149/month membership fee from medication cost — not a single all-inclusive price. Effective self-pay totals for semaglutide often run $294–$378/month, consistently more expensive than Luma Health's flat rate. As of 2026, Ro has also stopped accepting new patients for compounded tirzepatide, redirecting them toward brand Zepbound through insurance navigation instead.
✓ Ro Strengths
- Video consultations with providers
- Optional metabolic lab work
- Integrated pharmacy (own facilities)
- 8+ year operating history
- Insurance nav for brand Wegovy/Zepbound
✗ Ro Limitations
- Separate ~$149/mo membership fee on top of medication
- Compounded tirzepatide not available to new patients (2026)
- Generalist multi-condition model
- Some plans require 3-month commitment
The Pricing Comparison That Actually Matters
The key insight in comparing Hims, Ro, and Luma Health is that starting price and maintenance price are different numbers — and most patients spend 70–80% of their treatment time at maintenance doses, not starting doses. For Hims specifically, the entire pricing basis has shifted from compounded dose-tiers toward branded flat pricing, which changes the comparison method entirely.
| Scenario | Hims | Ro Body | Luma Health |
|---|---|---|---|
| Sema (compounded, if available) | Verify directly | ~$149/mo fee + medication | $197/mo |
| Sema effective monthly total | Verify directly | ~$294–$378/mo | $197/mo flat |
| Wegovy injectable (brand, self-pay) | ~$299/mo | Insurance-dependent | N/A (compounded only) |
| 12-mo total (Hims brand Wegovy) | ~$3,588 | ~$3,528–$4,536 (compounded sema) | $2,364 |
| Compounded tirzepatide | Discontinued | Not for new patients (2026) | $297/mo flat |
Full Three-Way Feature Comparison
| Factor | Hims | Ro Body | Luma Health |
|---|---|---|---|
| Primary medication model (2026) | Transitioning to branded | Compounded + brand nav | Compounded only |
| Wegovy (brand, self-pay) | ~$299/mo | Insurance-dependent | Not offered (compounded instead) |
| Compounded sema availability | Uncertain — verify directly | Available | ✓ $197/mo flat |
| Dose-tier increases (compounded) | N/A | Yes | ✓ None |
| Consultation model | Async (questionnaire) | ✓ Video + async | Async (all included) |
| Metabolic lab work | Not standard | ✓ Available | Not included |
| Insurance nav (brand) | ✓ Novo Nordisk partnership | ✓ Wegovy/Zepbound pathway | Cash-pay focus |
| Pharmacy named publicly | Not prominently | Integrated (own facilities) | ✓ VialsRX, TX #35264 |
| Contract required | Some plans | Some plans (3 mo) | ✓ None |
| Clinical specialization | Generalist (many conditions) | Multi-condition + weight focus | GLP-1 + metabolic health |
| Platform longevity | ✓ 2017, NYSE listed | ✓ 2017, well-funded | Newer platform |
| Named clinical provider | Not prominently | Ro-employed/contracted | ✓ Wasef Health, PC |
Who Each Platform Is Right For
Choose Hims If...
- You specifically want FDA-approved brand-name Wegovy or Ozempic through an established, publicly traded platform
- You already use Hims for other health needs and want everything on one platform
- You are comfortable with self-pay branded pricing (~$299/mo) rather than seeking the lowest-cost compounded option
- You will verify current medication availability directly, given the platform's active 2026 transition
Choose Ro If...
- You want video consultations with your provider rather than async questionnaire-only
- You are insured and want to pursue brand-name Wegovy or Zepbound through insurance coordination
- Metabolic lab work integration in your treatment decisions matters to you
- You want the platform stability and operational track record of a well-established, well-funded company
★ Choose Luma Health If...
- You want flat-rate pricing at every dose — $197/mo sema and $297/mo tirz, never changing regardless of dose tier
- Pharmacy transparency matters — VialsRX (TX #35264) publicly named and independently verifiable
- You are a cash-pay patient planning 6+ months of treatment and need cost predictability without navigating a shifting medication lineup
- No contracts, no commitment periods, cancel anytime with no penalty
Predictable pricing.
No shifting medication lineup.
Compounded semaglutide $197/month flat. VialsRX pharmacy (TX Board #35264). No contracts. Wasef Health, PC clinical oversight.
Start With Luma Health →Frequently Asked Questions
It depends on what you prioritize. Hims has transitioned toward FDA-approved branded Wegovy and Ozempic through a Novo Nordisk supply agreement following a 2026 legal settlement, at approximately $299/month self-pay. Ro offers compounded options plus clinical depth — video consultations, optional metabolic labs, and insurance navigation for brand-name GLP-1 — and maintains an integrated pharmacy model. For cash-pay patients primarily interested in the most predictable all-in cost for compounded medication, Luma Health's $197/month flat rate is lower than both Hims' branded pricing and Ro's maintenance-dose pricing, while offering more pharmacy transparency than either.
This is uncertain and actively changing. Hims launched a compounded oral semaglutide pill in February 2026, suspended it after a legal dispute with Novo Nordisk, then settled and signed a direct supply agreement for FDA-approved branded Wegovy and Ozempic. Hims has stated it is winding down its compounded semaglutide offering in favor of the branded lineup, with the transition targeted for completion by mid-2026. Verify current medication options directly at hims.com before enrolling, as this has changed multiple times.
Yes. Ro's Ro Body program includes video consultation options with licensed providers — a meaningful clinical differentiator compared to Hims' primarily asynchronous model. For patients who want real-time conversation about their medical history, goals, side effects, or dose adjustments, Ro's video consultation capability provides a more engaged clinical experience. Luma Health uses asynchronous intake reviewed by licensed clinicians through Wasef Health, PC — no video consultations, but all consultations and dose adjustments are included in the flat $197/month rate.
Yes. Ro's integrated pharmacy model and insurance coordination capability give them a genuine pathway for patients with commercial insurance who want to pursue prior authorization for brand-name Wegovy or Zepbound. Hims has a similar pathway now through its Novo Nordisk partnership. Luma Health focuses exclusively on cash-pay compounded alternatives and does not navigate insurance for brand-name GLP-1 — but at $197/month flat for compounded semaglutide, no insurance coordination is needed.
For compounded semaglutide specifically, Luma Health's $197/month flat rate is generally lower than Ro's maintenance-dose compounded pricing ($199–$249/month) and lower than Hims' current branded Wegovy pricing (~$299/month). For patients who want the same price from day 1 through month 18 regardless of dose or medication category, Luma Health's flat rate eliminates the price uncertainty that both Hims' evolving lineup and Ro's dose-tier structure carry.
For any remaining compounded offerings, Hims does not prominently disclose its specific compounding pharmacy partner in public marketing materials. For branded Wegovy and Ozempic, medication is supplied through Hims' direct agreement with Novo Nordisk. Ro uses its own integrated pharmacy facilities. Luma Health publicly names VialsRX (Texas State Board of Pharmacy license #35264), which patients can verify independently at pharmacy.texas.gov before providing any payment information.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. PubMed 33567185
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PubMed 35658024
- Hims & Hers Health, Inc. Hims & Hers Announces Strategic Shift for US Weight Loss Business. Investor Press Release, 2026. investors.hims.com
- U.S. Food and Drug Administration. Human Drug Compounding — Section 503A. FDA.gov
- NABP. Compounding Pharmacy Accreditation. nabp.pharmacy
- Hims & Hers Health. Weight Loss Program. hims.com
- Ro Body. Weight Loss Program. ro.co
- NIDDK. Prescription Medications to Treat Overweight & Obesity. niddk.nih.gov